Extended survival outcomes are becoming increasingly common after a diagnosis of multiple myeloma. What are some of the therapies responsible for these advances, and how far are we extending survival? Further, we’re learning that certain combination therapies are more effective for certain patients. How can we determine which patients are viable candidates for a specific treatment regimen? Dr. James Berenson, founding president and chief executive officer of the Institute for Myeloma and Bone Cancer Research in West Hollywood, Calif., probes these issues and more with host Dr. Mark Nolan Hill.
